The 9 most recent market catalysts affecting $PMN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 65
Guggenheim Maintains Buy on ProMIS Neurosciences, Raises Price Target to $100
Guggenheim analyst Yatin Suneja has maintained a 'Buy' rating on ProMIS Neurosciences (PMN) and raised the price target from $69 to $100. This upgrade signals a strong vote of conf…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 85
ProMIS Neurosciences Q2 EPS $(1.28) Beats $(1.38) Estimate
ProMIS Neurosciences (PMN) announced its Q2 earnings, reporting a loss of $(1.28) per share. This figure not only beat the analyst consensus estimate of $(1.38) by 7.25% but also m…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 65
Guggenheim Maintains Buy on ProMIS Neurosciences, Raises Price Target to $69
Guggenheim analyst Eddie Hickman maintained a 'Buy' rating on ProMIS Neurosciences (PMN) and substantially raised the price target from $35 to $69. This action signals increased co…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 85
ProMIS Neurosciences shares are trading higher. The company announced blinded six-month interim safety and biomarker results for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s disease trial.
This headline is a significant corporate catalyst for ProMIS Neurosciences, as positive interim clinical trial data for a lead drug candidate in a major disease like Alzheimer's ca…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 85
Small-Cap ProMIS Neurosciences Says Lead Drug Shows Encouraging Action in Early Alzheimer's Study
ProMIS Neurosciences reported encouraging blinded interim results from its Phase 1b PRECISE-AD trial for PMN310, an Alzheimer's drug. The key takeaway is the favorable safety profi…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 65
Chardan Capital Maintains Buy on ProMIS Neurosciences, Raises Price Target to $33
Chardan Capital's analyst Keay Nakae has maintained a 'Buy' rating on ProMIS Neurosciences (PMN) and significantly raised the price target from $20 to $33. This action indicates in…
Jul 27, 2026
Corporate Catalyst
Bullish
Impact 75
ProMIS Neurosciences shares are trading higher after the company announced it will host a webinar to discuss its six-month blinded interim data from the PRECISE-AD Phase 1b trial evaluating PMN310 in patients with early Alzheimer's disease.
This headline indicates a significant corporate catalyst for ProMIS Neurosciences. The announcement of a webinar to discuss six-month blinded interim data from a Phase 1b trial for…
Jul 27, 2026
Corporate Catalyst
Neutral
Impact 75
ProMIS Neurosciences Announces July 28 Webinar To Discuss Six-Month Blinded Interim Data From PMN310 PRECISE-AD Phase 1b Trial In Early Alzheimer's
The upcoming webinar for ProMIS Neurosciences' PMN310 Phase 1b data is a significant event for the biotechnology sector, particularly for companies focused on Alzheimer's disease. …
Jul 27, 2026
Corporate Catalyst
Neutral
Impact 65
Chardan Capital Initiates Coverage On ProMIS Neurosciences with Buy Rating, Announces Price Target of $20
Chardan Capital's initiation of coverage on ProMIS Neurosciences (PMN) with a 'Buy' rating and a $20 price target is a positive development for the company. Analyst coverage, espec…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.